Cargando…

Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Koeberle, Dieter, Thuerlimann, Beat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2007
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969866/ http://dx.doi.org/10.1007/s10549-007-9858-3

Ejemplares similares

Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98
por: Koeberle, Dieter, et al.
Publicado: (2007)

Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer
por: Regan, Meredith M, et al.
Publicado: (2011)

Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor–Positive, Early Breast Cancer
por: Buechler, Steven A, et al.
Publicado: (2019)

The early days of letrozole
por: Bhatnagar, Ajay S.
Publicado: (2008)

The discovery and mechanism of action of letrozole
por: Bhatnagar, Ajay S.
Publicado: (2007)

A decade of letrozole: FACE
por: O’Shaughnessy, Joyce
Publicado: (2008)

Combined letrozole and clomiphene versus letrozole and clomiphene alone in infertile patients with polycystic ovary syndrome [Erratum]
Publicado: (2017)

Letrozole in advanced breast cancer: the PO25 trial
por: Mouridsen, Henning T.
Publicado: (2007)

Letrozole in the neoadjuvant setting the P024 trial
por: Ellis, Matthew J., et al.
Publicado: (2007)

Letrozole in the extended adjuvant setting: MA.17
por: Goss, Paul E.
Publicado: (2008)

Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer in Korea
por: Beom, Seung Hoon, et al.
Publicado: (2017)

Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98
por: Alkner, S., et al.
Publicado: (2017)

European guidance for the diagnosis and management of osteoporosis in postmenopausal women
por: Kanis, J. A., et al.
Publicado: (2008)

Do BIG1-98 and ZOFAST demand a change in guidelines for endocrine therapy?
por: Smith, Ian E
Publicado: (2009)

Erratum: The Role of Hysteroscopy in Evaluating Postmenopausal Asymptomatic Women with Thickened Endometrium
Publicado: (2018)

Erratum to: The Roles of Menopausal-specific Quality of Life on Breast Cancer Screening Beliefs in Menopausal and Postmenopausal Women
por: Cheng, Winnie Lai-Sheung, et al.
Publicado: (2019)

Erratum to: Sclerosing Stromal Tumor of the Ovary in Postmenopausal Women: A Report of Two Cases
por: Lee, Chae Min, et al.
Publicado: (2015)

Association of chemerin levels and bone mineral density in Chinese obese postmenopausal women: Erratum
Publicado: (2016)

Erratum to: Effect of Lactobacillus Fermentum as a Probiotic Agent on Bone Health in Postmenopausal Women
por: Han, Hee Soo, et al.
Publicado: (2023)

Effect of Romosozumab on Trabecular Bone Score Compared to Anti-Resorptive Agents in Postmenopausal Women with Osteoporosis
por: Jeong, Chaiho, et al.
Publicado: (2022)

Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective
por: Mistry, Rohit, et al.
Publicado: (2018)

Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate
por: Fein, Luis, et al.
Publicado: (2023)

Erratum to: Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation
por: Kearns, Ben, et al.
Publicado: (2017)

Erratum for Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study
por: Dhaliwal, Ruban, et al.
Publicado: (2020)

Long-term efficacy and safety of letrozole for the adjuvant treatment of early breast cancer in postmenopausal women: a review
por: Monnier, Alain
Publicado: (2009)

Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India
por: Loi, Sherene, et al.
Publicado: (2021)

Correction: Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate
por: Fein, Luis, et al.
Publicado: (2023)

Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+/HER2− locally advanced or metastatic breast cancer: a Brazilian private payer perspective
por: Buehler, Anna Maria, et al.
Publicado: (2021)

Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: A phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy
por: Krainick-Strobel, Ute E, et al.
Publicado: (2008)

Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study
por: Jakob, F, et al.
Publicado: (2012)

Surgery Should Complement Endocrine Therapy for Elderly Postmenopausal Women with Hormone Receptor-Positive Early-Stage Breast Cancer
por: Nguyen, Olivier, et al.
Publicado: (2012)

Alcohol, Hormones, and Postmenopausal Women
por: Longnecker, Matthew P., et al.
Publicado: (1998)

The genetic association between osteoprotegerin (OPG) gene polymorphisms and bone mineral density (BMD) in postmenopausal women: A meta-analysis: Erratum
Publicado: (2019)

Effect of vitamin D vaginal suppository on sexual functioning among postmenopausal women: A three-arm randomized controlled clinical trial
por: Sarebani, Zinat, et al.
Publicado: (2023)

The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1–98 trial
por: Desmedt, Christine, et al.
Publicado: (2009)

Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)
por: Kim, Jisun, et al.
Publicado: (2014)

Erratum to “Development of liquid crystal displays and related improvements to their performances”: [Proc. Jpn. Acad., Ser. B 98, No. 9, 493–516]
por: KOBAYASHI, Shunsuke, et al.
Publicado: (2023)

Anti-Müllerian hormone and letrozole levels in boys with constitutional delay of growth and puberty treated with letrozole or testosterone
por: Kohva, E, et al.
Publicado: (2020)

Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy
por: Oing, C., et al.
Publicado: (2023)

SAT-222 Hormone Responses Associated with Letrozole Ovulation Induction in Anovulatory Women with PCOS
por: Hadnott, Tracy, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vkojracgl48gnilms0vq9e12nu